KIT and gastrointestinal stromal tumor: The preclinical data strongly support the clinical development of M4205 which is currently being investigated as IDRX-42 in a phase I first-in-human study with promising early efficacy signals across different KIT mutations (32) in participants with advanced (metastatic and/or surgically unresectable) GIST.